[go: up one dir, main page]

NO20060982L - Dispergerende formulering for et anti-inflammatorisk middel - Google Patents

Dispergerende formulering for et anti-inflammatorisk middel

Info

Publication number
NO20060982L
NO20060982L NO20060982A NO20060982A NO20060982L NO 20060982 L NO20060982 L NO 20060982L NO 20060982 A NO20060982 A NO 20060982A NO 20060982 A NO20060982 A NO 20060982A NO 20060982 L NO20060982 L NO 20060982L
Authority
NO
Norway
Prior art keywords
inflammatory agent
dispersant formulation
organ
dispersant
formulation
Prior art date
Application number
NO20060982A
Other languages
English (en)
Inventor
Niki Ann Waldron
Nancy Jean Britten
John W Hallberg
Jeffrey Watts
Iii John Williams Burns
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20060982L publication Critical patent/NO20060982L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

En metode er frembrakt for behandling og/eller forebyggelse av en inflammatorisk tilstand i et væskeholdig organ med en naturlig ytre åpning, slik som et melkeproduserende dyrs jur eller et subj ekts øre. Oppfinnelsen vedrører også et dispergerbart farinasøytisk preparat som er egnet for infusjon inn i organet i samsvar med metoden ifølge oppfinnelsen, og en prosess til fremstilling av et slikt preparat.
NO20060982A 2003-07-31 2006-02-28 Dispergerende formulering for et anti-inflammatorisk middel NO20060982L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49212103P 2003-07-31 2003-07-31
PCT/IB2004/002461 WO2005009436A1 (en) 2003-07-31 2004-07-19 Dispersible formulation of an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
NO20060982L true NO20060982L (no) 2006-05-02

Family

ID=34103027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060982A NO20060982L (no) 2003-07-31 2006-02-28 Dispergerende formulering for et anti-inflammatorisk middel

Country Status (14)

Country Link
EP (1) EP1651210A1 (no)
JP (1) JP2007500691A (no)
KR (1) KR100780983B1 (no)
CN (1) CN1829510A (no)
AU (1) AU2004258745A1 (no)
BR (1) BRPI0412581A (no)
CA (1) CA2533101A1 (no)
CO (1) CO5650245A2 (no)
IL (1) IL172735A0 (no)
MX (1) MXPA06001288A (no)
NO (1) NO20060982L (no)
RU (1) RU2319508C2 (no)
WO (1) WO2005009436A1 (no)
ZA (1) ZA200600096B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina
GB0711776D0 (en) * 2007-06-18 2007-07-25 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
RU2392929C2 (ru) * 2007-06-20 2010-06-27 Общество С Ограниченной Ответственностью "Гамаветфарм" Средство для стимуляции выброса стволовых кроветворных клеток в кровоток
UA111147C2 (uk) * 2009-11-11 2016-04-11 Байєр Б.В. Способи та композиції для лікування або профілактики зовнішнього отиту
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
DK2366408T3 (da) * 2010-03-01 2012-10-22 Salvat Lab Sa Vandige, klare opløsninger af fluocinolonacetonid til behandling af inflammation i øret
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
RU2486905C1 (ru) * 2012-05-28 2013-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ФГБОУ ВПО "КубГТУ") Средство для лечения мастита у животных
CN102784161A (zh) * 2012-08-01 2012-11-21 张吉川 一种治疗急慢性中耳炎的特效滴耳液
ES2763352T3 (es) * 2013-01-14 2020-05-28 Infirst Healthcare Ltd Composiciones de solución sólida y uso en inflamación crónica
SG11201505243PA (en) * 2013-02-04 2015-08-28 Infirst Healthcare Ltd Compositions and methods for treating chronic inflammation and inflammatory diseases
LV15071B (lv) * 2015-07-14 2016-02-20 Rīgas Stradiņa Universitāte Kompozīcija subklīniska mastīta ārstēšanai govīm
CA2994702A1 (en) 2015-08-05 2017-02-09 Children's Medical Center Corporation Compositions with permeation enhancers for drug delivery
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
KR101738815B1 (ko) * 2015-08-27 2017-05-23 심민보 혈소판 풍부 혈장을 포함하는 감각신경성 난청 또는 이명을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법
WO2019191547A1 (en) * 2018-03-29 2019-10-03 Yale University Novel fully synthetic and semisynthetic pleuromutilin derivatives as new antibiotics and their preparation
EP3829540A1 (en) * 2018-08-01 2021-06-09 Novilla Pharmaceuticals, Inc. Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2751697C1 (ru) * 2020-09-09 2021-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Донской государственный аграрный университет" Средство для лечения отитов наружного слухового прохода у собак
KR102461699B1 (ko) * 2021-05-21 2022-11-03 현대약품 주식회사 벤지다민염산염을 포함하는 안정성이 개선된 가글액
KR102785852B1 (ko) * 2021-12-03 2025-03-26 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물
WO2023101418A1 (ko) * 2021-12-03 2023-06-08 (주)인비보텍 난청 또는 이명의 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
JPH08511559A (ja) * 1993-06-18 1996-12-03 スミスクライン・ビーチャム・コーポレイション 軟外皮ゼラチンに封入された粒子
JP4155593B2 (ja) * 1994-10-26 2008-09-24 ノバルティス・アクチエンゲゼルシャフト 医薬組成物
NZ309624A (en) * 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
AU2001274858A1 (en) * 2000-06-08 2001-12-17 Board Of Regents, The University Of Texas System Heterocycle derivatives and methods of use for treating anthrax infection
PL363153A1 (en) * 2000-06-16 2004-11-15 Hercules Incorporated Chemically-modified antimicrobial peptides, compositions and methods of production and use
US20040033938A1 (en) * 2000-09-12 2004-02-19 Britten Nancy J. Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
CA2416563A1 (en) * 2000-09-12 2002-03-21 Pharmacia & Upjohn Company Pharmaceutical composition having specific water activity
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions

Also Published As

Publication number Publication date
IL172735A0 (en) 2006-04-10
JP2007500691A (ja) 2007-01-18
ZA200600096B (en) 2007-02-28
WO2005009436A8 (en) 2005-05-06
KR100780983B1 (ko) 2007-11-30
CA2533101A1 (en) 2005-02-03
EP1651210A1 (en) 2006-05-03
MXPA06001288A (es) 2006-04-11
CO5650245A2 (es) 2006-06-30
CN1829510A (zh) 2006-09-06
WO2005009436A1 (en) 2005-02-03
RU2319508C2 (ru) 2008-03-20
RU2006101628A (ru) 2006-08-27
BRPI0412581A (pt) 2006-09-19
KR20060031873A (ko) 2006-04-13
AU2004258745A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
NO20060982L (no) Dispergerende formulering for et anti-inflammatorisk middel
NO20054777L (no) Dispergerbar farmasoytisk sammesetning for behandling av mastitt og/eller otittforstyrrelser
Nayak et al. Experimental evaluation of ethanolic extract of Carapa guianensis L. leaf for its wound healing activity using three wound models
Tandon et al. Hepatoprotective activity of Vitex negundo leaf extract against anti-tubercular drugs induced hepatotoxicity
NO20054260L (no) Disepergebar formulering av en anti-inflammatorisk forbindelse
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
AR047067A1 (es) Metodos para el uso de bifidobacterias probioticas para animales de compania
WO2010070675A8 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
EP4058193A4 (en) SEPARABLE CASSETTE AND EMBEDDING FRAME WITH CONNECTORS AND METHODS FOR PREPARING BIOPSY TISSUE SAMPLES
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
NO20070293L (no) Aryl-substituerte piperazinderivater
NO20056223L (no) Preparat til behandling av infeksjon hos kveg og svin
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
WO2007112453A3 (en) Methods amd compositions for treating conditions
BRPI0512311A (pt) uso de meloxicam em medicina veterinária para o tratamento de doenças inflamatórias dolorosas
Reddy et al. Oral myiasis in children
Bourne et al. Veterinary issues related to bears (Ursidae)
AR044271A1 (es) Suplemento dietetico y metodo para el tratamiento y prevencion de ulceras en el tracto digestivo en equinos y otros animales
CN108096226A (zh) 一种含聚赖氨酸的口腔溃疡贴膜及其制备方法
Kroigaard et al. KCa3. 1 channel downregulation and impaired endothelium‐derived hyperpolarization‐type relaxation in pulmonary arteries from chronically hypoxic rats
DE102017113263A1 (de) Pharmazeutische Zusammensetzung enthaltend Bakterienstämme aus der Familie der Lactobacillaceae und Molke
WO2018230931A3 (ko) 대사성 질환 예방 또는 치료용 조성물
MD2516C2 (ro) Remediu medicamentos antiinflamator, antiseptic şi antifungic sub formă de gel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application